51. 全身性強皮症
[臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210]
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2016-003417-95-NL (EUCTR) | 18/09/2018 | 09/07/2018 | Proof of mechanism study of GSK2330811 in diffuse cutaneous systemic sclerosis. | A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore efficacy of GSK2330811 in participants with diffuse cutaneous systemic sclerosis. - Proof of mechanism study of GSK2330811 in diffuse cutaneous systemic sclerosis. | Systemic sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GSK2330811 Solution for Injection, 100mg/ml Product Code: GSK2330811 INN or Proposed INN: GSK2330811 Other descriptive name: GSK2330811 | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United States;Canada;Netherlands;United Kingdom | ||
2 | NCT03041025 (ClinicalTrials.gov) | June 5, 2017 | 31/1/2017 | Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis | A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis | Scleroderma, Systemic | Drug: GSK2330811;Drug: Placebo | GlaxoSmithKline | NULL | Completed | 18 Years | N/A | All | 35 | Phase 2 | United States;Canada;Netherlands;United Kingdom |
3 | EUCTR2016-003417-95-GB (EUCTR) | 13/01/2017 | 24/10/2016 | Proof of mechanism study of GSK2330811 in diffuse cutaneous systemic sclerosis. | A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore efficacy of GSK2330811 in participants with diffuse cutaneous systemic sclerosis. - Proof of mechanism study of GSK2330811 in diffuse cutaneous systemic sclerosis. | Systemic sclerosis MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GSK2330811 Solution for Injection, 100mg/ml Product Code: GSK2330811 INN or Proposed INN: GSK2330811 Other descriptive name: GSK2330811 | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United States;Netherlands;United Kingdom | ||
4 | NCT02386436 (ClinicalTrials.gov) | April 21, 2015 | 6/3/2015 | A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects | A Phase I, Randomised, Double-blind (Sponsor Open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects | Scleroderma, Systemic | Drug: GSK2330811;Drug: Placebo | GlaxoSmithKline | NULL | Completed | 18 Years | 65 Years | All | 41 | Phase 1 | United Kingdom |